symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
DVHGF,0.2138,2.041445,34,31371090,0,0.1597-0.6599,0.0541,Devonian Health Group Inc.,USD,,,,Other OTC,PNK,Biotechnology,https://groupedevonian.com,"Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.",Mr. Pierre J. Montanaro,Healthcare,CA,,,"360, rue des Entrepreneurs",Québec,QC,G5V 4T1,,0,https://financialmodelingprep.com/image-stock/DVHGF.png,2022-09-19,True,False,False,False,False
